Insider Shareholders with Direct Ownership of Stoke Therapeutics, Inc. (STOK)
This section provides a comprehensive overview of the insiders with direct ownership of Stoke Therapeutics, Inc. (STOK). You can find detailed information about the size and nature of each insider's ownership stake, as well as the latest updates on their holdings.
Stoke Therapeutics, Inc. Insider List
| Insider | Adquired | Disposed | Held | # of Trades | Last Transaction |
|---|---|---|---|---|---|
| 61,739 | 30,000 | 31,739 $421,176 | 5 |
Feb 13, 2024
Added 50.0%
|
|
| 80,500 | 103,500 | 27,000 $358,290 | 10 |
May 20, 2024
Reduced 8.98%
|
|
|
Gene Liau
EVP Research & Preclinical Dev |
52,695 | 44,844 | 21,351 $283,327 | 10 |
Mar 02, 2021
Reduced 11.96%
|
|
Stephen J Tulipano
Former CFO |
124,260 | 104,116 | 20,746 $275,299 | 13 |
Mar 19, 2024
Reduced 16.56%
|
|
Jonathan Allan
GENERAL COUNSEL & CORP SEC |
16,074 | 18,022 | 2,598 $34,475 | 6 |
May 20, 2024
Reduced 76.8%
|
|
Barry Ticho
CHIEF MEDICAL OFFICER |
90,411 | 263,073 | 2,485 $32,975 | 36 |
Nov 01, 2024
Reduced 80.1%
|
| 12,500 | 12,500 | 0 $0 | 2 |
Mar 01, 2021
Reduced 100.0%
|
|
|
Huw M. Nash
Chief Business Officer |
274,475 | 279,352 | 0 $0 | 40 |
Jul 02, 2024
Reduced 100.0%
|
|
Apple Tree Partners Iv, L.P.
> 10% Shareholder |
375,000 | 17,161,713 | 0 $0 | 2 |
Jun 28, 2021
Reduced 100.0%
|